Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 379

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 379
---
 Heritas Diagnostics’ commercial operations are designed to deliver precise diagnostic information through clinical genetic tests, along with a range of treatment alternatives via detailed reports, aimed at enhancing patient care. This service is commercialized through clinical laboratories, which offer these tests to patients and healthcare providers. These laboratories are onboarded and receive continuous commercial and technical assessment to offer the genetic tests to their customer base. Clinical laboratories collect samples, ship them to our Argentine Wet -Labfor processing, and once results are complete, these are sent to the clinical laboratory to be sent to their customer. Once samples are processed, the Company generates reports with the results, which CIBIC then delivers to patients and physicians. For the services provided, the Company sets a price for each category of tests, which CIBIC pays per test requested to Heritas Argentina. CIBIC then sells these tests to end consumers at a price it determines. Revenue generated from selling the tests and other genetics sequencing services is recognized at a point in time when the reports with the results of the tests are sent to CIBIC. Heritas Diagnostics conducts its marketing and sales through key partners, including CIBIC and Meyer. For more information, please refer to “ OmnigenicsAI Management’s Discussion and Analysis of Financial Condition and Results of Operations — Basis of Preparation and Significant Accounting Policies — Revenue recognition.” In respect of Heritas Diagnostics, marketing and sales is conducted by distribution partners. We support these by employing targeted marketing strategies to healthcare institutions, clinics, and medical professionals. These strategies include informative webinars, educational content and referrals, with the objective of generating awareness over the importance of clinical genetic tests for the health management of patients and their families. Business Development Overview We are focused on making comprehensive, high -qualitygenetic information more accessible and instrumental to the healthcare ecosystem and directly to the general population, to revolutionize health management. As we develop our products and grow, we expect to expand and evolve in the near future in the stages described below. Strategic partnerships and consortium development We are committed to driving transformational change in the healthcare industry by leveraging strategic partnerships and building a robust consortium of market participants. Our decade -longjourney of scientific and clinical innovation has laid the foundation for this next phase of growth. We are focused on creating a collaborative ecosystem that maximizes our competitive advantages while ensuring sustainable and scalable growth. The key elements of our approach include: • Hybrid laboratory infrastructure: we plan to employ a hybrid model for the wet lab processing requirements of the consortium, using both our own facilities and